CoChat

Ovarian Hypertension: Polycystic Ovary Syndrome

Open access
Bentley-Lewis, Rhonda, Seely, Ellen, Dunaif, Andrea · 2011 · Endocrinology and Metabolism Clinics of North America
Cited by 78

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Hypertension is a significant contributor to the risk for cardiovascular disease. The increased prevalence of hypertension in women with polycystic ovary syndrome (PCOS) may contribute to the increased risk of cardiovascular disease in these women. Whether hypertension is associated with PCOS independent of obesity remains controversial. Nevertheless, detection and subsequent treatment of hypertension in this population should decrease the adverse sequelae from hypertensive cardiovascular disease. Treatment of risk factors inherent to PCOS, such as hyperandrogenism, insulin resistance, and obesity, may minimize the risk not only for the development of hypertension but also for incident cardiovascular disease independent of hypertension.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ecl.2011.01.009

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 97

  1. Burghen, 1980, Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease, J Clin Endocrinol Metab, 50, 113, 10.1210/jcem-50-1-113 · DOI · Paper page
  2. Dunaif, 1987, Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia, J Clin Endocrinol Metab, 65, 499, 10.1210/jcem-65-3-499 · DOI · Paper page
  3. Dunaif, 1997, Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis, Endocr Rev, 18, 774
  4. Ehrmann, 2005, Polycystic ovary syndrome, N Engl J Med, 352, 1223, 10.1056/NEJMra041536 · DOI · Paper page
  5. Polson, 1988, Polycystic ovaries—a common finding in normal women, Lancet, 1, 870, 10.1016/S0140-6736(88)91612-1 · DOI · Paper page
  6. Legro, 2005, Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype, J Clin Endocrinol Metab, 90, 2571, 10.1210/jc.2004-0219 · DOI · Paper page
  7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, Fertil Steril, 81, 19, 10.1016/j.fertnstert.2003.10.004 · DOI · Paper page
  8. Robinson, 1993, The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries, Clin Endocrinol (Oxf), 39, 351, 10.1111/j.1365-2265.1993.tb02376.x · DOI · Paper page
  9. Adams, 2004, Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome, J Clin Endocrinol Metab, 89, 4343, 10.1210/jc.2003-031600 · DOI · Paper page
  10. Azziz, 2004, The prevalence and features of the polycystic ovary syndrome in an unselected population, J Clin Endocrinol Metab, 89, 2745, 10.1210/jc.2003-032046 · DOI · Paper page
  11. Asunción, 2000, A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain, J Clin Endocrinol Metab, 85, 2434
  12. Diamanti-Kandarakis, 1999, A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile, J Clin Endocrinol Metab, 84, 4006, 10.1210/jcem.84.11.6148 · DOI · Paper page
  13. Moran, 2010, Prevalence of polycystic ovary syndrome and related disorders in Mexican women, Gynecol Obstet Invest, 69, 274, 10.1159/000277640 · DOI · Paper page
  14. Knochenhauer, 1998, Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study, J Clin Endocrinol Metab, 83, 3078
  15. Lo, 2006, Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome, J Clin Endocrinol Metab, 91, 1357, 10.1210/jc.2005-2430 · DOI · Paper page
  16. Marshall, 1999, Neuroendocrine aspects of polycystic ovary syndrome, Endocrinol Metab Clin North Am, 28, 295, 10.1016/S0889-8529(05)70071-2 · DOI
  17. Eagleson, 2000, Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone, J Clin Endocrinol Metab, 85, 4047
  18. Franks, 1989, Polycystic ovary syndrome, Trends Endocrinol Metab, 1, 60, 10.1016/1043-2760(89)90003-9 · DOI
  19. Reid, 1981, Induction of ovulation and pregnancy with pulsatile luteinizing hormone releasing factor: dosage and mode of delivery, Fertil Steril, 36, 553, 10.1016/S0015-0282(16)45850-4 · DOI
  20. Legro, 1998, Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome, Proc Natl Acad Sci U S A, 95, 14956, 10.1073/pnas.95.25.14956 · DOI · Paper page
  21. Wickenheisser, 2000, Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells, J Clin Endocrinol Metab, 85, 2304
  22. Dunaif, 1999, Insulin action in the polycystic ovary syndrome, Endocrinol Metab Clin North Am, 28, 341, 10.1016/S0889-8529(05)70073-6 · DOI · Paper page
  23. Book, 1999, Selective insulin resistance in the polycystic ovary syndrome, J Clin Endocrinol Metab, 84, 3110
  24. Escobar-Morreale, 2005, The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery, J Clin Endocrinol Metab, 90, 6364, 10.1210/jc.2005-1490 · DOI · Paper page
  25. Laitinen, 2003, Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms, Int J Obes Relat Metab Disord, 27, 710, 10.1038/sj.ijo.0802301 · DOI · Paper page
  26. Hoeger, 2007, Obesity and lifestyle management in polycystic ovary syndrome, Clin Obstet Gynecol, 50, 277, 10.1097/GRF.0b013e31802f54c8 · DOI · Paper page
  27. Grodstein, 1994, Body mass index and ovulatory infertility, Epidemiology, 5, 247, 10.1097/00001648-199403000-00016 · DOI · Paper page
  28. Legro, 2002, Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome, J Clin Endocrinol Metab, 87, 2134, 10.1210/jcem.87.5.8387 · doi:10.1210/jcem.87.5.8387 · Paper page
  29. Legro, 2002, Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity, J Clin Endocrinol Metab, 87, 2128, 10.1210/jcem.87.5.8513 · doi:10.1210/jcem.87.5.8513 · Paper page
  30. Urbanek, 1999, Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin, Proc Natl Acad Sci U S A, 96, 8573, 10.1073/pnas.96.15.8573 · DOI · Paper page
  31. Urbanek, 2000, Allelic variants of the follistatin gene in polycystic ovary syndrome, J Clin Endocrinol Metab, 85, 4455
  32. Urbanek, 2007, Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype, J Clin Endocrinol Metab, 92, 4191, 10.1210/jc.2007-0761 · DOI · Paper page
  33. Ewens, 2010, Family-based analysis of candidate genes for polycystic ovary syndrome, J Clin Endocrinol Metab, 95, 2306, 10.1210/jc.2009-2703 · DOI · Paper page
  34. National Cholesterol Education Program (NCEP) Expert Panel on Detection E and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002, Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 · DOI · Paper page
  35. Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement, Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404 · DOI · Paper page
  36. Alberti, 1998, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet Med, 15, 539, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
  37. Essah, 2006, Metabolic syndrome in women with polycystic ovary syndrome, Fertil Steril, 86, S18, 10.1016/j.fertnstert.2006.04.013 · DOI
  38. Sam, 2005, Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome, J Clin Endocrinol Metab, 90, 4797, 10.1210/jc.2004-2217 · DOI · Paper page
  39. Bentley-Lewis, 2007, The metabolic syndrome in women, Nat Clin Pract Endocrinol Metab, 3, 696, 10.1038/ncpendmet0616 · DOI
  40. Legato, 2000, Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy, Am J Cardiol, 86, 15L, 10.1016/S0002-9149(00)01463-6 · DOI
  41. Valkenburg, 2008, A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study, J Clin Endocrinol Metab, 93, 470, 10.1210/jc.2007-1756 · DOI · Paper page
  42. Carmina, 2009, Cardiovascular risk and events in polycystic ovary syndrome, Climacteric, 12, 22, 10.1080/13697130903003842 · DOI · Paper page
  43. Conway, 1992, Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome, Clin Endocrinol (Oxf), 37, 119, 10.1111/j.1365-2265.1992.tb02295.x · DOI · Paper page
  44. Talbott, 1998, Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study, J Clin Epidemiol, 51, 415, 10.1016/S0895-4356(98)00010-9 · DOI · Paper page
  45. Vrbíková, 2003, Cardiovascular risk factors in young Czech females with polycystic ovary syndrome, Hum Reprod, 18, 980, 10.1093/humrep/deg218 · DOI · Paper page
  46. Elting, 2001, Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population, Hum Reprod, 16, 556, 10.1093/humrep/16.3.556 · DOI · Paper page
  47. Holte, 1996, Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?, Hum Reprod, 11, 23, 10.1093/oxfordjournals.humrep.a019028 · DOI · Paper page
  48. Orbetzova, 2003, Role of 24-hour monitoring in assessing blood pressure changes in polycystic ovary syndrome, Folia Med (Plovdiv), 45, 21
  49. Wild, 2000, Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study, Hum Fertil (Camb), 3, 101, 10.1080/1464727002000198781 · DOI · Paper page
  50. Dahlgren, 1992, Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones, Fertil Steril, 57, 505, 10.1016/S0015-0282(16)54892-4 · DOI · Paper page
  51. Farquhar, 2007, Laparoscopic ‘drilling’ by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD001122.pub3 · DOI · Paper page
  52. Buttram, 1975, Post-ovarian wedge resection adhesive disease, Fertil Steril, 26, 874, 10.1016/S0015-0282(16)41351-8 · DOI
  53. Barcellos, 2007, Impact of body mass index on blood pressure levels in patients with polycystic ovary syndrome, Arq Bras Endocrinol Metabol, 51, 1104, 10.1590/S0004-27302007000700013 · DOI · Paper page
  54. Arslanian, 2001, Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease, J Clin Endocrinol Metab, 86, 66
  55. Luque-Ramírez, 2007, Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome, J Clin Endocrinol Metab, 92, 2141, 10.1210/jc.2007-0190 · DOI · Paper page
  56. Zimmermann, 1992, Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance, J Clin Endocrinol Metab, 75, 508
  57. Sampson, 1996, Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome, Clin Endocrinol (Oxf), 45, 623, 10.1046/j.1365-2265.1996.00863.x · DOI · Paper page
  58. Cibula, 2000, Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome, Hum Reprod, 15, 785, 10.1093/humrep/15.4.785 · DOI · Paper page
  59. Boomsma, 2008, Pregnancy complications in women with polycystic ovary syndrome, Semin Reprod Med, 26, 72, 10.1055/s-2007-992927 · DOI · Paper page
  60. Ludwig, 2005, Risk during pregnancy and birth after assisted reproductive technologies: an integral view of the problem, Semin Reprod Med, 23, 363, 10.1055/s-2005-923394 · DOI
  61. Sun, 2009, Assisted reproductive technology and placenta-mediated adverse pregnancy outcomes, Obstet Gynecol, 114, 818, 10.1097/AOG.0b013e3181b76bd1 · DOI
  62. Möhlig, 2004, The polycystic ovary syndrome per se is not associated with increased chronic inflammation, Eur J Endocrinol, 150, 525, 10.1530/eje.0.1500525 · DOI · Paper page
  63. Escobar-Morreale, 2003, Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women, Diabetologia, 46, 625, 10.1007/s00125-003-1090-z · DOI
  64. Ketel, 2008, Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance, J Clin Endocrinol Metab, 93, 3365, 10.1210/jc.2008-0626 · DOI · Paper page
  65. Ketel, 2010, Greater arterial stiffness in polycystic ovary syndrome (PCOS) is an obesity—but not a PCOS-associated phenomenon, J Clin Endocrinol Metab, 95, 4566, 10.1210/jc.2010-0868 · DOI · Paper page
  66. Spranger, 2004, Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome, Clin Endocrinol (Oxf), 61, 738, 10.1111/j.1365-2265.2004.02159.x · DOI · Paper page
  67. Lindholm, 2010, Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome, Gynecol Endocrinol, 26, 743, 10.3109/09513590.2010.487592 · DOI
  68. Guzick, 1996, Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study, Am J Obstet Gynecol, 174, 1224, 10.1016/S0002-9378(96)70665-8 · DOI · Paper page
  69. Luque-Ramírez, 2007, Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome, Hum Reprod, 22, 3197, 10.1093/humrep/dem324 · DOI · Paper page
  70. Carmina, 2006, Endothelial dysfunction in PCOS: role of obesity and adipose hormones, Am J Med, 119, 356.e1, 10.1016/j.amjmed.2005.10.059 · DOI · Paper page
  71. Christian, 2003, Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 88, 2562, 10.1210/jc.2003-030334 · DOI · Paper page
  72. Talbott, 2004, Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome, J Clin Endocrinol Metab, 89, 5454, 10.1210/jc.2003-032237 · DOI · Paper page
  73. Talbott, 2008, Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women?, Vasc Health Risk Manag, 4, 453, 10.2147/VHRM.S1452 · DOI · Paper page
  74. Chen, 2007, Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome, Hypertension, 49, 1442, 10.1161/HYPERTENSIONAHA.106.083972 · DOI · Paper page
  75. Riccioni, 2009, The effect of antihypertensive drugs on carotid intima media thickness: an up-to-date review, Curr Med Chem, 16, 988, 10.2174/092986709787581923 · doi:10.2174/092986709787581923
  76. Zavaroni, 1995, Association between salt sensitivity and insulin concentrations in patients with hypertension, Am J Hypertens, 8, 855, 10.1016/0895-7061(95)00152-F · DOI
  77. Resnick, 1992, Cellular ions in hypertension, insulin resistance, obesity, and diabetes: a unifying theme, J Am Soc Nephrol, 3, S78, 10.1681/ASN.V34s78 · DOI
  78. Lord, 2003, Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome, Cochrane Database Syst Rev, 3
  79. Diamanti-Kandarakis, 2007, Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome, Metabolism, 56, 129, 10.1016/j.metabol.2006.09.006 · DOI
  80. Hattori, 2002, Vascular smooth muscle cell activation by glycated albumin (Amadori adducts), Hypertension, 39, 22, 10.1161/hy1201.097300 · DOI · Paper page
  81. Orio, 2005, Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study, J Clin Endocrinol Metab, 90, 6072, 10.1210/jc.2005-0965 · DOI · Paper page
  82. Kannel, 2000, Fifty years of Framingham study contributions to understanding hypertension, J Hum Hypertens, 14, 83, 10.1038/sj.jhh.1000949 · DOI · Paper page
  83. Cupisti, 2008, Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome, Eur J Endocrinol, 158, 711, 10.1530/EJE-07-0515 · DOI · Paper page
  84. Glintborg, 2004, Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis, Fertil Steril, 82, 1570, 10.1016/j.fertnstert.2004.06.040 · DOI
  85. Yildirir, 2006, Heart rate variability in young women with polycystic ovary syndrome, Ann Noninvasive Electrocardiol, 11, 306, 10.1111/j.1542-474X.2006.00122.x · DOI · Paper page
  86. Muniyappa, 2007, Cardiovascular actions of insulin, Endocr Rev, 28, 463, 10.1210/er.2007-0006 · DOI · Paper page
  87. Müller-Wieland, 1998, Metabolic syndrome and hypertension: pathophysiology and molecular basis of insulin resistance, Basic Res Cardiol, 93, 131, 10.1007/s003950050238 · DOI
  88. Battaglia, 2010, Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study, Fertil Steril, 94, 1417, 10.1016/j.fertnstert.2009.05.044 · DOI
  89. Kriplani, 2010, Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome, Contraception, 82, 139, 10.1016/j.contraception.2010.02.009 · DOI
  90. Fruzzetti, 2010, Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome, Fertil Steril, 94, 1793, 10.1016/j.fertnstert.2009.10.016 · DOI
  91. Guido, 2004, Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study, J Clin Endocrinol Metab, 89, 2817, 10.1210/jc.2003-031158 · DOI · Paper page
  92. Ober, 1978, Spironolactone therapy for hirsutism in a hyperandrogenic woman, Ann Intern Med, 89, 643, 10.7326/0003-4819-89-5-643 · DOI
  93. Rathnayake, 2010, Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss, Dermatol Clin, 28, 611, 10.1016/j.det.2010.03.011 · DOI
  94. Christy, 2005, Spironolactone for hirsutism in polycystic ovary syndrome, Ann Pharmacother, 39, 1517, 10.1345/aph.1G025 · DOI
  95. Ganie, 2004, Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study, J Clin Endocrinol Metab, 89, 2756, 10.1210/jc.2003-031780 · DOI · Paper page
  96. Armanini, 2007, Treatment of polycystic ovary syndrome with spironolactone plus licorice, Eur J Obstet Gynecol Reprod Biol, 131, 61, 10.1016/j.ejogrb.2006.10.013 · DOI
  97. Eid, 2005, Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass, Surg Obes Relat Dis, 1, 77, 10.1016/j.soard.2005.02.008 · DOI · Paper page

Cited by

See all 78

Metadata

Authors
Bentley-Lewis, R., Seely, E., & Dunaif, A.
Venue
Endocrinology and Metabolism Clinics of North America
Publisher
Elsevier BV
Published
2011-06
Volume
40
Issue
2
Pages
433-449
ISSN
0889-8529 (ISSN-L)
OpenAlex
W1989897876
Cited by
78
References
20
FWCI
5.46
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.